The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin as Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
2 other identifiers
interventional
678
17 countries
74
Brief Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of 2 different doses of canagliflozin administered as monotherapy compared with placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3 diabetes-mellitus-type-2
Started Mar 2010
Typical duration for phase_3 diabetes-mellitus-type-2
74 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2010
CompletedFirst Submitted
Initial submission to the registry
March 4, 2010
CompletedFirst Posted
Study publicly available on registry
March 5, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2012
CompletedResults Posted
Study results publicly available
June 3, 2013
CompletedFebruary 23, 2017
June 1, 2013
1.4 years
March 4, 2010
April 15, 2013
February 15, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Change in HbA1c From Baseline to Week 26 (Main Study)
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.
Day 1 (Baseline) and Week 26
Change in HbA1c From Baseline to Week 26 (High Glycemic Substudy)
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.
Day 1 (Baseline) and Week 26
Secondary Outcomes (14)
Percentage of Patients With HbA1c <7% at Week 26 (Main Study)
Week 26
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 (Main Study)
Day 1 (Baseline) and Week 26
Change in 2-hour Post-prandial Glucose From Baseline to Week 26 (Main Study)
Day 1 (Baseline) and Week 26
Percent Change in Body Weight From Baseline to Week 26 (Main Study)
Day 1 (Baseline) and Week 26
Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 (Main Study)
Day 1 (Baseline) and Week 26
- +9 more secondary outcomes
Study Arms (3)
Canagliflozin 100 mg
EXPERIMENTALEach patient will receive 100 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).
Canagliflozin 300 mg
EXPERIMENTALEach patient will receive 300 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).
Placebo/Sitagliptin
EXPERIMENTALIn the Main Study, each patient will receive matching placebo once daily for 26 weeks and will then switch from placebo to 100 mg of sitagliptin once daily until Week 52.
Interventions
One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)
One matching placebo capsule orally once daily for 26 weeks (Main Study)
One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 (Main Study)
Eligibility Criteria
You may qualify if:
- All patients must have a diagnosis of T2DM
- Patients in the main study must have a Hemoglobin A1c (HbA1c) between \>=7% and \<=10% and a fasting plasma glucose (FPG) \<270 mg/dL (15 mmol/L)
- Patients in the High Glycemic Cohort Substudy must have an HbA1c between \>10% and \<=12% and a FPG \<=350 mg/dL (19.44 mmol/L)
You may not qualify if:
- History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (78)
Unknown Facility
Phoenix, Arizona, United States
Unknown Facility
Concord, California, United States
Unknown Facility
Greenbrae, California, United States
Unknown Facility
Los Angeles, California, United States
Unknown Facility
Spring Valley, California, United States
Unknown Facility
Colorado Springs, Colorado, United States
Unknown Facility
Denver, Colorado, United States
Unknown Facility
Northglenn, Colorado, United States
Unknown Facility
Springfield, Illinois, United States
Unknown Facility
Evansville, Indiana, United States
Unknown Facility
Baton Rouge, Louisiana, United States
Unknown Facility
Metairie, Louisiana, United States
Unknown Facility
Meridian, New Jersey, United States
Unknown Facility
Albuquerque, New Mexico, United States
Unknown Facility
New York, New York, United States
Unknown Facility
West Seneca, New York, United States
Unknown Facility
Mooresville, North Carolina, United States
Unknown Facility
Perryopolis, Pennsylvania, United States
Unknown Facility
Pittsburgh, Pennsylvania, United States
Unknown Facility
Taylors, South Carolina, United States
Unknown Facility
Dallas, Texas, United States
Unknown Facility
Houston, Texas, United States
Unknown Facility
San Antonio, Texas, United States
Unknown Facility
Norfolk, Virginia, United States
Unknown Facility
Horn, Austria
Unknown Facility
Salzburg, Austria
Unknown Facility
Vienna, Austria
Unknown Facility
Barranquilla, Colombia
Unknown Facility
Bogotá, Colombia
Unknown Facility
Pärnu, Estonia
Unknown Facility
Tartu, Estonia
Unknown Facility
Viljandi, Estonia
Unknown Facility
Guatemala City, Guatemala
Unknown Facility
Reykjavik, Iceland
Unknown Facility
Bangalore, India
Unknown Facility
Hyderabad, India
Unknown Facility
Nagpur, India
Unknown Facility
Kaunas, Lithuania
Unknown Facility
Klaipėda, Lithuania
Unknown Facility
Šiauliai, Lithuania
Unknown Facility
Vilnius, Lithuania
Unknown Facility
Vilnius Lt, Lithuania
Unknown Facility
Kelantan, Malaysia
Unknown Facility
Kuala Lumpur, Malaysia
Unknown Facility
Aguascalientes, Mexico
Unknown Facility
Guadalajara, Mexico
Unknown Facility
Mexico City, Mexico
Unknown Facility
Monterrey, Mexico
Unknown Facility
Zapopan, Mexico
Unknown Facility
Makati, Philippines
Unknown Facility
Manila, Philippines
Unknown Facility
Marikina City, Philippines
Unknown Facility
Pasay, Philippines
Unknown Facility
Katowice, Poland
Unknown Facility
Torun, Poland
Unknown Facility
Warsaw, Poland
Unknown Facility
Fajardo, Puerto Rico
Unknown Facility
Ponce, Puerto Rico
Unknown Facility
San Juan, Puerto Rico
Unknown Facility
Baia Mare, Romania
Unknown Facility
Brasov, Romania
Unknown Facility
Bucharest, Romania
Unknown Facility
Târgu Mureş, Romania
Unknown Facility
Halfway, South Africa
Unknown Facility
Pretoria, South Africa
Unknown Facility
Busan, South Korea
Unknown Facility
Goyang-si, South Korea
Unknown Facility
Jeonju, South Korea
Unknown Facility
Seoul, South Korea
Unknown Facility
Wŏnju, South Korea
Unknown Facility
Alcalá de Henares, Spain
Unknown Facility
Elche, Spain
Unknown Facility
Girona, Spain
Unknown Facility
Pozuelo de Alarcón, Spain
Unknown Facility
Gothenburg, Sweden
Unknown Facility
Lund, Sweden
Unknown Facility
Malmo, Sweden
Unknown Facility
Skene, Sweden
Related Publications (17)
Davies MJ, Merton K, Vijapurkar U, Yee J, Qiu R. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data. Cardiovasc Diabetol. 2017 Mar 21;16(1):40. doi: 10.1186/s12933-017-0517-7.
PMID: 28327140DERIVEDPfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol. 2017 Feb 27;16(1):29. doi: 10.1186/s12933-017-0511-0.
PMID: 28241822DERIVEDGilbert RE, Mende C, Vijapurkar U, Sha S, Davies MJ, Desai M. Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials. Diabetes Ther. 2017 Apr;8(2):451-458. doi: 10.1007/s13300-017-0232-0. Epub 2017 Feb 14.
PMID: 28197834DERIVEDQiu R, Balis D, Xie J, Davies MJ, Desai M, Meininger G. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Curr Med Res Opin. 2017 Mar;33(3):553-562. doi: 10.1080/03007995.2016.1271780. Epub 2017 Jan 4.
PMID: 27977934DERIVEDJohn M, Cerdas S, Violante R, Deerochanawong C, Hassanein M, Slee A, Canovatchel W, Hamilton G. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. Int J Clin Pract. 2016 Sep;70(9):775-85. doi: 10.1111/ijcp.12868.
PMID: 27600862DERIVEDWatts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016 Jan;101(1):157-66. doi: 10.1210/jc.2015-3167. Epub 2015 Nov 18.
PMID: 26580237DERIVEDLavalle-Gonzalez FJ, Eliaschewitz FG, Cerdas S, Chacon Mdel P, Tong C, Alba M. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Curr Med Res Opin. 2016;32(3):427-39. doi: 10.1185/03007995.2015.1121865. Epub 2016 Jan 14.
PMID: 26579834DERIVEDBlonde L, Woo V, Mathieu C, Yee J, Vijapurkar U, Canovatchel W, Meininger G. Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Curr Med Res Opin. 2015 Nov;31(11):1993-2000. doi: 10.1185/03007995.2015.1082991. Epub 2015 Sep 28.
PMID: 26373629DERIVEDGavin JR 3rd, Davies MJ, Davies M, Vijapurkar U, Alba M, Meininger G. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2015;31(9):1693-702. doi: 10.1185/03007995.2015.1067192. Epub 2015 Sep 4.
PMID: 26121561DERIVEDCefalu WT, Stenlof K, Leiter LA, Wilding JP, Blonde L, Polidori D, Xie J, Sullivan D, Usiskin K, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015 Jun;58(6):1183-7. doi: 10.1007/s00125-015-3547-2. Epub 2015 Mar 27.
PMID: 25813214DERIVEDWeir MR, Januszewicz A, Gilbert RE, Vijapurkar U, Kline I, Fung A, Meininger G. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2014 Dec;16(12):875-82. doi: 10.1111/jch.12425. Epub 2014 Oct 20.
PMID: 25329038DERIVEDUsiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med. 2014 May;126(3):16-34. doi: 10.3810/pgm.2014.05.2753.
PMID: 24918789DERIVEDWeir MR, Kline I, Xie J, Edwards R, Usiskin K. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014 Sep;30(9):1759-68. doi: 10.1185/03007995.2014.919907. Epub 2014 May 22.
PMID: 24786834DERIVEDSinclair A, Bode B, Harris S, Vijapurkar U, Mayer C, Fung A, Shaw W, Usiskin K, Desai M, Meininger G. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord. 2014 Apr 18;14:37. doi: 10.1186/1472-6823-14-37.
PMID: 24742013DERIVEDPolidori D, Mari A, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia. 2014 May;57(5):891-901. doi: 10.1007/s00125-014-3196-x. Epub 2014 Mar 1.
PMID: 24585202DERIVEDNyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, Ways K, Usiskin K. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014 Jun;30(6):1109-19. doi: 10.1185/03007995.2014.890925. Epub 2014 Feb 21.
PMID: 24517339DERIVEDStenlof K, Cefalu WT, Kim KA, Jodar E, Alba M, Edwards R, Tong C, Canovatchel W, Meininger G. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014 Feb;30(2):163-75. doi: 10.1185/03007995.2013.850066. Epub 2013 Oct 28.
PMID: 24073995DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Vice President, Franchise Medical Leader, Cardiovascular & Metabolism Franchise
- Organization
- Janssen Research & Development, LLC
Study Officials
- STUDY DIRECTOR
Janssen Research & Development, LLC Clinical Trial
Janssen Research & Development, LLC
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 4, 2010
First Posted
March 5, 2010
Study Start
March 1, 2010
Primary Completion
August 1, 2011
Study Completion
March 1, 2012
Last Updated
February 23, 2017
Results First Posted
June 3, 2013
Record last verified: 2013-06